<DOC>
	<DOCNO>NCT02032264</DOCNO>
	<brief_summary>To evaluate benefit use next generation sequence assess embryonic aneuploidy . All viable blastocyst biopsied cryopreserved future transfer . After final embryo cryopreserved , patient randomize either intervention group control group . Patients doctor blind randomization study completion . A Double Embryo Transfer ( DET ) perform either screen unscreened embryo depend randomization . A Single Embryo Transfer ( SET ) may occur case one embryo available transfer .</brief_summary>
	<brief_title>Next Generation Sequencing Screening Embryonic Ploidy Status</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<criteria>Patient undergo IVF/CCS ( PGD banking ) Patient meet ASRM guideline Double Embryo Transfer ( DET ) Donor Sperm OK AMH ≥ 1.2 FSH ≤ 12 BAFC ≥12 Max 1 prior fail IVF cycle patient 3545 year old Patient &lt; 35 year old MUST 1 prior fail IVF cycle Chronic endometrial insufficiency Use oocyte donor gestational carrier Medical contraindication Double Embryo Transfer ( DET ) Male Factor ( &lt; 100,000 sperm surgical sperm ) Communicating hydrosalpinx ( HSG ) Single gene disorder sex selection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Next generation sequence</keyword>
	<keyword>Embryonic aneuploidy</keyword>
</DOC>